Edition:
India

Collegium Pharmaceutical Inc (COLL.OQ)

COLL.OQ on NASDAQ Stock Exchange Global Select Market

24.67USD
20 Apr 2018
Change (% chg)

$-0.76 (-2.99%)
Prev Close
$25.43
Open
$25.34
Day's High
$25.36
Day's Low
$24.37
Volume
116,810
Avg. Vol
177,481
52-wk High
$29.80
52-wk Low
$7.37

Chart for

About

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides... (more)

Overall

Beta: --
Market Cap(Mil.): $348.59
Shares Outstanding(Mil.): 29.57
Dividend: --
Yield (%): --

Financials

  COLL.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -3.65 -- --
ROI: -99.46 14.84 14.38
ROE: -101.15 16.34 16.07

BRIEF-Collegium Appoints Shirley Kuhlmann As General Counsel

* COLLEGIUM ANNOUNCES THE APPOINTMENT OF SHIRLEY KUHLMANN AS GENERAL COUNSEL Source text for Eikon: Further company coverage:

19 Mar 2018

BRIEF-Collegium Reports Q4 Loss Per Share $0.54

* COLLEGIUM REPORTS FOURTH QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

08 Mar 2018

BRIEF-Collegium To Host Conference Call To Discuss Fourth Quarter 2017 Financial Results And Provide Corporate Update

* COLLEGIUM TO HOST CONFERENCE CALL TO DISCUSS FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE Source text for Eikon: Further company coverage:

27 Feb 2018

BRIEF-Collegium Filed Patent Infringement Lawsuit Against Teva Pharma USA

* COLLEGIUM PHARMA SAYS FILED PATENT INFRINGEMENT LAWSUIT IN U.S. DISTRICT COURT FOR DISTRICT OF DELAWARE AGAINST TEVA PHARMACEUTICALS USA INC

23 Feb 2018

BRIEF-Janus Henderson Group Reports 10.1 Pct Passive Stake In Collegium Pharmaceutical

* JANUS HENDERSON GROUP PLC REPORTS 10.1 PERCENT PASSIVE STAKE IN COLLEGIUM PHARMACEUTICAL AS OF DEC 31, 2017 - SEC FILING Source text : [http://bit.ly/2mvIp5l] Further company coverage:

11 Jan 2018

BRIEF-Depomed Announces Closing Of Nucynta Commercialization Agreement With Collegium Pharmaceutical

* DEPOMED ANNOUNCES CLOSING OF NUCYNTA COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL

10 Jan 2018

BRIEF-BioDelivery Sciences Reacquires Onsolis From Collegium Pharmaceutical

* BIODELIVERY SCIENCES REACQUIRES ONSOLIS® FROM COLLEGIUM PHARMACEUTICAL

15 Dec 2017

BRIEF-Depomed Announces Nucynta® Commercialization Agreement With Collegium Pharmaceutical

* DEPOMED ANNOUNCES NUCYNTA® COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL

05 Dec 2017

BRIEF-Collegium To License Rights To Commercialize Nucynta Franchise

* COLLEGIUM TO LICENSE RIGHTS TO COMMERCIALIZE NUCYNTA FRANCHISE

05 Dec 2017

BRIEF-Collegium reports third quarter loss of $0.45 per share

* Collegium reports third quarter financial results and provides corporate update

09 Nov 2017

Earnings vs. Estimates